Affordable Access

Amyloid associated proteins in Alzheimer's and prion disease.

Authors
  • Veerhuis, R1
  • Boshuizen, R S
  • Familian, A
  • 1 Institute for Clinical and Experimental Neurosciences-VU, Departments of Psychiatry Vrije Universiteit University Medical Center, 1007 MB Amsterdam, The Netherlands. [email protected] , (Netherlands)
Type
Published Article
Journal
Current drug targets. CNS and neurological disorders
Publication Date
Jun 01, 2005
Volume
4
Issue
3
Pages
235–248
Identifiers
PMID: 15975027
Source
Medline
Language
English
License
Unknown

Abstract

Clustering of activated microglia in Abeta deposits is related to accumulation of amyloid associated factors and precedes the neurodegenerative changes in AD. Microglia-derived pro-inflammatory cytokines are suggested to be the driving force in AD pathology. Inflammation-related proteins, including complement factors, acute-phase proteins, pro-inflammatory cytokines, that normally are locally produced at low levels, are increasingly synthesized in Alzheimer's disease (AD) brain. Similar to AD, in prion diseases (Creutzfeldt-Jakob disease, Gerstmann-Sträussler-Scheinker disease and experimentally scrapie infected mouse brain) amyloid associated factors and activated glial cells accumulate in amyloid deposits of conformational changed prion protein (PrPres). Biological properties of Abeta and prion (PrP) peptides, including their potential to activate microglia, relate to Abeta and PrP peptide fibrillogenic abilities that are influenced by certain amyloid associated factors. However, since small oligomers of amyloid forming peptides are more toxic to neurons than large fibrils, certain amyloid associated factors that enhance fibril formation, may sequester the potentially harmful Abeta and PrP peptides from the neuronal microenvironment. In this review the positive and negative actions of amyloid associated factors on amyloid peptide fibril formation and on the fibrillation state related activation of microglia will be discussed. Insight in these mechanisms will enable the design of specific therapies to prevent neurodegenerative diseases in which amyloid accumulation and glial activation are prominent early features.

Report this publication

Statistics

Seen <100 times